{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.72","value":"57.0"},{"groupId":"OG001","spread":"21.16","value":"60.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Global Health Status/QoL: Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.56","value":"47.8"},{"groupId":"OG001","spread":"19.61","value":"48.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Global Health Status/QoL: End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.42","value":"67.4"},{"groupId":"OG001","spread":"29.67","value":"67.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Role (Functional Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.86","value":"47.6"},{"groupId":"OG001","spread":"27.04","value":"49.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Role (Functional Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.19","value":"74.9"},{"groupId":"OG001","spread":"21.70","value":"83.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Emotional (Functional Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.19","value":"67.6"},{"groupId":"OG001","spread":"22.62","value":"72.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Emotional (Functional Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.38","value":"79.6"},{"groupId":"OG001","spread":"20.74","value":"84.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Cognitive(Functional Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.61","value":"69.6"},{"groupId":"OG001","spread":"22.64","value":"77.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Cognitive (Functional Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.94","value":"72.2"},{"groupId":"OG001","spread":"27.02","value":"75.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Social (Functional Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.35","value":"63.1"},{"groupId":"OG001","spread":"24.76","value":"69.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Social (Functional Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.89","value":"60.0"},{"groupId":"OG001","spread":"23.07","value":"61.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Fatigue (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.02","value":"50.8"},{"groupId":"OG001","spread":"25.77","value":"50.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Fatigue (Symptom Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.41","value":"96.7"},{"groupId":"OG001","spread":"11.54","value":"94.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Nausea/Vomiting (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.75","value":"88.7"},{"groupId":"OG001","spread":"16.52","value":"92.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Nausea/Vomiting (Symptom Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.77","value":"61.1"},{"groupId":"OG001","spread":"24.70","value":"65.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Pain (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.42","value":"51.2"},{"groupId":"OG001","spread":"28.33","value":"53.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Pain (Symptom Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.56","value":"25.2"},{"groupId":"OG001","spread":"25.74","value":"19.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Dyspnea (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.57","value":"40.5"},{"groupId":"OG001","spread":"26.61","value":"24.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Dyspnea (Symptom Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.72","value":"32.6"},{"groupId":"OG001","spread":"31.87","value":"29.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Insomnia (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.35","value":"36.9"},{"groupId":"OG001","spread":"34.69","value":"29.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Insomnia (Symptom Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.52","value":"22.2"},{"groupId":"OG001","spread":"22.39","value":"14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Appetite Loss (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.52","value":"34.5"},{"groupId":"OG001","spread":"28.02","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Appetite Loss (Symptom Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.99","value":"13.3"},{"groupId":"OG001","spread":"20.37","value":"11.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Constipation (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"34.69","value":"25.0"},{"groupId":"OG001","spread":"29.50","value":"19.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Constipation (Symptom Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.14","value":"17.8"},{"groupId":"OG001","spread":"23.23","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Diarrhea (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.34","value":"19.0"},{"groupId":"OG001","spread":"25.95","value":"16.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"41"}],"units":"Participants"}],"title":"Diarrhea (Symptom Scale): End of Treatment"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.52","value":"22.2"},{"groupId":"OG001","spread":"25.85","value":"17.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"title":"Financial Difficulties (Symptom Scale): Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.28","value":"16.7"},{"groupId":"OG001","spread":"22.03","value":"12.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Financial Difficulties (Symptom Scale): End of Treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"The EORTC QLQ-C30 contains 30 items across 5 functional scales (physical, role, cognitive, emotional, and social), 9 symptom scales (fatigue, nausea and vomiting, pain, dyspnea, sleep disturbance, appetite loss, constipation, diarrhea, and financial difficulties) and a QOL scale. Most of the 30 items had 4 response levels (not at all, a little, quite a bit, and very much), with 2 questions relying on a 7-point numeric rating scale. Each subscale raw score were linearly transformed to a total score between 0 to 100. For the functional scales and the global health status/QOL scale, higher scores represent better QOL; for the symptom scales, lower scores represent better QOL. The Physical domain of the functional subscale is reported in the secondary outcome measure 7.","dispersionType":"Standard Deviation","groups":[{"description":"Pomalidomide 4 mg, capsules, orally, once daily on Days 1 to 21 of each 28-day cycle, plus dexamethasone 40 mg, (or 20 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG000","title":"Pomalidomide 4 mg + Dexamethasone 40 mg"},{"description":"Ixazomib 4 mg as starting dose, capsules, orally, once daily on Days 1, 8, and 15 of each 28-day cycle, with escalation to 5.5 mg at the start of Cycle 2 for participants who tolerated the 4 mg dose in Cycle 1, plus dexamethasone 20 mg (or 10 mg if participant is aged \\>=75 years), tablets, orally, once daily on Days 1, 2, 8, 9, 15, 16, 22, and 23 of every 28-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or sponsor termination of study up to 2 years.","id":"OG001","title":"Ixazomib 4 mg + Dexamethasone 20 mg"}],"paramType":"MEAN","populationDescription":"ITT PRO Population included participants with a measurement at study entry and at least one post study entry measurement for at least 1 subscale on all 3 questionnaires (EORTC QLQ-C30, EORTC QLQ-MY20 and EQ-5D-5L). Number analyzed are the number of participants with data available for analyses at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline and End of Treatment (Up to 28 cycles, each cycle was of 28 days)","title":"HRQOL Based on EORTC QLQ-C30 SubScale Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}